KT-253
kymera therapeutics
['kymera ']
today at the congress in frankfurt, we'll present exciting data from preclinical oncology models for kt-253, our novel, highly potent and selective heterobifunctional #mdm2 degrader. learn more here: #tpd 
Advancing the field of targeted protein degradation to deliver breakthrough medicines for previously untreatable diseases